Catalys Pacific Fund, LP 4
4 · Mineralys Therapeutics, Inc. · Filed Feb 16, 2023
Insider Transaction Report
Form 4
Slingsby Brian Taylor
Director10% Owner
Transactions
- Conversion
Common Stock
2023-02-14+4,314,093→ 8,944,579 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2023-02-14−2,171,342→ 0 total(indirect: See footnote)→ Common Stock (2,171,342 underlying) - Conversion
Series B Preferred Stock
2023-02-14−2,142,751→ 0 total(indirect: See footnote)→ Common Stock (2,142,751 underlying) - Purchase
Common Stock
2023-02-14$16.00/sh+250,000$4,000,000→ 9,194,579 total(indirect: See Footnote)
Footnotes (2)
- [F1]Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.
- [F2]Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.